Hernández DMSE

Idioma: Español
Referencias bibliográficas: 31
Paginas: 296-301
Archivo PDF: 52.40 Kb.

RESUMEN

Propósito: Evaluar la seguridad y eficacia del tratamiento adyuvante con bevacizumab intravítreo previo a cirugía de vitrectomía en retinopatía diabética proliferativa avanzada.
Pacientes y métodos: Se realizó un estudio ensayo clínico controlado. Se incluyeron 40 ojos de 40 pacientes con los siguientes criterios de inclusión: retinopatía diabética proliferativa avanzada con presencia de desprendimiento de retina traccional, Hb1aC ‹7. Se aleatorizaron los pacientes en dos grupos: en el grupo A se realizó vitrectomía pars plana convencional, mientras que en el grupo B se aplicó dosis de bevacizumab intravítreo 48 horas antes de la vitrectomía. A todos los pacientes se les realizó toma de agudeza visual y presión intraocular a la semana, 1 mes, 3 y seis meses postoperatorios.
Resultados: Se apreciaron diferencias en cuanto a la capacidad visual a los 3 y 6 meses entre los dos grupos (p=0.002 y p=0.001) respectivamente, siendo el promedio de visión de –0.82 logMAR para el grupo A y -2.01 logMAR para el grupo B a los 6 meses de seguimiento. Se apreció también menor tiempo efectivo de vitrectomía en el grupo A (8.05 minutos) versus grupo B (16.8 minutos).
Conclusiones: El tratamiento adyuvante de bevacizumab intravítreo facilita la cirugía de vitrectomía en retinopatía diabética proliferativa avanzada.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Chen HX, Gore-Langton RE, Cheson BD. Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab. Oncology (Williston Park) 2001; 15(8):1017, 1020, 1023-6.

2. Gragoudas ES, Adamis AP, Cunningham ET Jr y cols. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351(27):2805-16.

3. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results.Ophthalmol Clin North Am 2006; 19(3):361-72.

4. Michels S, Rosenfeld PJ, Puliafito CA y cols. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology 2005; 112(6):1035-47.

5. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36(4):336-9.

6. Avery RL, Pieramici DJ, Rabena MD y cols. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113(3):363-372.

7. Sima P, Zoran T. Long-term results of vitreous surgery for proliferative diabetic retinopathy. Doc Ophthalmol 1994; 87(3):223-32.

8. Arevalo JF, Wu L, Sanchez JG y cols. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2007; [en prensa].

9. Ishikawa K, Honda S, Tsukahara Y y cols. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye; [en prensa].

10. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26(6):699-700.

11. Elliott A, Flanagan D. Macular detachment following laser treatment for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228(5):438-41.

12. Charles S. Diabetic retinopathy vitrectomy study. Arch Ophthalmol 1986; 104(4): 486, 488.

13. Diabetic Retinopathy Vitrectomy Study. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. (DRVS) report #1. Ophthalmology 1985; 92(4):492-502.

14. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 1985; 103(11):1644-52.

15. Shea M. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial-Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988; 95(10):1307-20.

16. The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial—Diabetic Retinopathy Vitrectomy Study Report 4. Ophthalmology 1988; 95(10):1321-34.

17. Diabetic Retinopathy Vitrectomy Study Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Fouryear results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990; 108(7):958-64. Erratum in: Arch Ophthalmol 1990 Oct; 108(10):1452.

18. Faulborn J, Conway BP, Machemer R. Surgical complications of pars plana vitreous surgery. Ophthalmology 1978; 85(2):116-25.

19. Carter JB, Michels RG, Glaser BM y cols. Iatrogenic retinal breaks complicating pars plana vitrectomy. Ophthalmology 1990; 97(7):848-53.

20. Chagnon A, Payan J, Levy C, Chassain C. Intraocular pressure during vitrectomy in the diabetic patient. Bull Soc Ophtalmol Fr 1989; 89(1):171-8.

21. Thompson JT, Glaser BM, Michels RG y cols. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986; 93(3):279-82.

22. O’Grady GE. The use of intravitreal thrombin to control hemorrhage during vitrectomy. Ophthalmology 1986; 93(10):1367.

23. Imamura Y, Kamei M, Minami M y cols. Heparin-assisted removal of clotting preretinal hemorrhage during vitrectomy for proliferative diabetic retinopathy. Retina 2005; 25(6):793-5.

24. Siam AL. External diathermy treatment of proliferative diabetic retinopathy with vitreous haemorrhage. Br J Ophthalmol 1986; 70(2):118-21.

25. Ruiz-Moreno JM, Montero JA, Lugo F y cols. Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. Acta Ophthalmol Scand 2007; [En prensa] .

26. Yanyali A, Aytug B, Horozoglu F y cols. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007; 144(1):124-6.

27. Haritoglou C, Kook D, Neubauer A y cols. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9):999-1005.

28. Jonas JB, Spandau UH, Rensch F y cols. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007; 23(3):240-2.

29. Arevalo JF, Maia M, Flynn H Jr y cols. Tractional Retinal Detachment following Intravitreal Bevacizumab (Avastin(R)) in patients with Severe Proliferative Diabetic Retinopathy. Br J Ophthalmol 2007; [en prensa].

30. Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol 2007; 21(3):185-7.

31. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007; 21(4):245-57.